StockUK listing UK0GQULSECapital Destroyer

Active Biotech AB(0GQU) Stock Analysis

SEK --+0.00%
Reward37Moderate
Risk47Moderate
50%Data
SEK —+0.00 (+0.00%) Previous close · LSE
Market cap 8.09M
Reward Rating37 Moderate reward assessment · 50% data coverage
Bottom 5% of stocksView factors
Risk Rating47 Moderate risk assessment · 75% data coverage
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on 0GQU to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Active Biotech AB?

Active Biotech AB (publ), a biotechnology company, engages in the research, development, production, marketing, and sale of medical, chemical, and biotechnology products in Sweden.

AI Brief Pro

The brief on Active Biotech AB

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Active Biotech AB?

Active Biotech AB (publ), a biotechnology company, engages in the research, development, production, marketing, and sale of medical, chemical, and biotechnology products in Sweden. It is developing Tasquinimod, a small molecule immunomodulator, which is in Phase II clinical trial to treat hematological malignancies; Laquinimod, an immunomodulator for the treatment of severe inflammatory eye diseases, such as non-infectious non anterior uveitis; and Naptumomab estafenatox, a tumor targeting immunotherapy to treat patients with solid tumors. The company is listed on the LSE in UK, with a market capitalisation of 8.09M.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Risk profile appears balanced versus broad market conditions.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (37)
Company Information
SectorN/A
IndustryN/A
Beta1.341
Insider Activity
12M windowAwaiting coverage
LSE director-dealings coverage launching later this year. The data feed is in development.